TABLE OF CONTENTS
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY DRUG CATEGORY
5.1 ACID NEUTRALIZERS
5.1.1 ANTACIDS
5.1.2 H2 ANTAGONISTS
5.1.3 PROTON PUMP INHIBITORS
5.1.4 OTHERS
5.2 LAXATIVES AND ANTIDIARRHEAL
5.3 ANTIEMETIC
5.4 ANTI-INFLAMMATORY DRUGS
5.5 OTHER
6. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
6.1 ORAL
6.2 PARENTERAL
6.3 RECTAL
7. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, DISEASE TYPE
7.1 GASTROESOPHAGEAL REFLUX DISEASE
7.2 INFLAMMATORY BOWEL DISEASE
7.3 OTHER
8 EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET
8.1 HOSPITAL PHARMACIES
8.2 RETAIL PHARMACIES
8.3 OTHER
9. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY REGION
9.1 INTRODUCTION
9.2 EUROPE
9.2.1 WESTERN EUROPE
9.2.1.1 GERMANY
9.2.1.2 FRANCE
9.2.1.3 ITALY
9.2.1.3 SPAIN
9.2.1.5 UK
9.2.1.6 REST OF WESTERN EUROPE
9.2.2 EASTERN EUROPE
9.3 MIDDLE EAST & AFRICA
10. COMPETITIVE LANDSCAPE
10.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
10.1.1 STRATEGIC PARTNERSHIP
10.1.2 MERGER & ACQUISITION
11 COMPANY PROFILE
11.1 ABBVIE INC.
11.1.1 OVERVIEW
11.1.2 PRODUCT OVERVIEW
11.1.3 FINANCIALS
11.1.4 KEY DEVELOPMENTS
11.2 ASTRAZENECA
11.2.1 OVERVIEW
11.2.2 PRODUCT OVERVIEW
11.2.3 FINANCIALS
11.2.4 KEY DEVELOPMENTS
11.3 JOHNSON & JOHNSON
11.3.1 OVERVIEW
11.3.2 PRODUCT OVERVIEW
11.3.3 FINANCIALS
11.3.4 STRATEGY
11.3.5 KEY DEVELOPMENT
11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.4.1 OVERVIEW
11.4.2 PRODUCT OVERVIEW
11.4.3 FINANCIALS
11.4.4 KEY DEVELOPMENTS
11.5 ALLERGAN PLC
11.5.1 OVERVIEW
11.5.2 PRODUCT OVERVIEW
11.5.3 FINANCIALS
11.5.4 KEY DEVELOPMENTS
11.6 OTHERS